Essential Partners’s 10x Genomics TXG Stock Holding History

Essential Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$177K	Sell	4,608 -620	-12%	-$16.2K	0.08%	268
2026 Q1	$111K	Hold	5,228	–	–	0.04%	401
2025 Q4	$85.3K	Sell	5,228 -13	-0.2%	-$196	0.03%	485
2025 Q3	$61.3K	Buy	5,241 +36	+0.7%	+$469	0.02%	551
2025 Q2	$60.3K	Buy	+5,205	New	+$47.4K	0.02%	431

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's TXG Position: Q2 2026 in Review

Essential Partners reduced its 10x Genomics (TXG) stake by 12% in Q2 2026, selling an estimated $16.2K and leaving 4,608 shares worth $177K. The position accounts for 0.08% of the portfolio, ranked #268.

Essential Partners first reported a position in TXG in Q2 2025 and has held it in 5 quarters since. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Essential Partners held 4,608 shares of 10x Genomics worth $177K as of Q2 2026.
Essential Partners sold 620 10x Genomics shares in Q2 2026, an estimated $16.2K.
10x Genomics made up 0.08% of Essential Partners's portfolio in Q2 2026, its #268 holding.
Essential Partners first reported a position in 10x Genomics in Q2 2025 and has held it in 5 quarters since.
391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.